Dyax Employee Directory

Biotechnology ResearchMassachusetts, United States51-200 Employees

Dyax is a biotechnology company focused on developing and commercializing therapies for unmet medical needs. Based in Burlington, Massachusetts, it pursues a portfolio that includes a candidate DX-2930, a fully human monoclonal antibody intended to prevent hereditary angioedema (HAE) attacks, and KALBITOR (ecallantide), a treatment for acute HAE attacks. The company licenses its phage display technology through a Licensing and Funded Research Portfolio (LFRP), enabling partners to advance related candidates and collaborate on development. This structure positions Dyax as both a developer of internal programs and a platform provider for external partnerships.

Dyax was acquired by Shire in 2016, and the page indicates it is no longer actively monitored after the transaction. This context places its historical operations within the broader biotechnology landscape, centered on development and licensing of HAE-focused therapies.

Sign up for free to view info

Company overview Email format